AdrenaCard has developed a new class of drug delivery auto-injector that increases compliance for emergency medication. Contemporary devices suffer from low rates of ownership and carrying compliance. Their first drug-device product, an epinephrine auto-injector (EAI) for the severe allergy market, is currently in development and there are dozens of other prospective combinations available as they work to bring peace of mind to life for patients.
They have production ready designs, secured intellectual property, and a deep understanding of the care environment. They are seeking partners to join us as we go to market.View Resource